Figure 3 — Identification of immunotherapy biomarkers for improving the clinical outcome of homologous recombination deficiency patients with lung adenocarcinoma

Research Paper|Volume 15, Issue 16|pp. 8090–8112

Identification of immunotherapy biomarkers for improving the clinical outcome of homologous recombination deficiency patients with lung adenocarcinoma

Back to articleFigure 3(3 of 8)

100%

Figure 3.Mutational landscape of HRD and non-HRD patients. (A) Top 20 mutation landscape of HRD patients in the TCGA-LUAD cohort. (B) Top 20 mutation landscape of non-HRD patients in the TCGA-LUAD cohort. The genes in red boxes are actionable genes. (C) Overlapping information of HRD and non-HRD mutated genes; actionable genes are only in non-HRD.